This clinical trial is focused on studying a rare skin condition known as Netherton syndrome. This condition is a genetic disorder that affects the skin, hair, and immune system, often leading to red, scaly skin and other complications. The trial is testing a treatment called spesolimab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific targets in the body, potentially helping to treat certain diseases.

The purpose of this study is to evaluate how well spesolimab works in treating patients with Netherton syndrome. Participants in the study will receive either spesolimab or a placebo. The medication will be administered in two forms: as a solution for infusion, which is given through a vein, and as a solution for injection, which is given under the skin. The study will last for a period of time, during which participants will receive the treatment and be monitored for any changes in their condition.

Throughout the study, researchers will observe the participants to see if there is an improvement in their skin condition, such as a reduction in redness and scaling. They will also monitor for any side effects or adverse reactions to the treatment. The goal is to determine if spesolimab is a safe and effective treatment option for people with Netherton syndrome.